Difference between revisions of "Interferon alfa-2a (Roferon-A)"
m |
|||
| Line 19: | Line 19: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Immunotherapy]] | ||
| + | |||
| + | [[Category:Basal cell and squamous cell skin cancer medications]] | ||
| + | [[Category:Chronic myelogenous leukemia medications]] | ||
| + | [[Category:Follicular lymphoma medications]] | ||
| + | [[Category:Melanoma medications]] | ||
| + | [[Category:Neuroendocrine tumor medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
| + | [[Category:Transplant medications]] | ||
Revision as of 19:30, 8 September 2014
General information
Class/mechanism: Immune system activator; binds to human type 1 interferon, activating downstream intracellular signal transduction pathways initially mediated by the JAK/STAT pathway. Interferon α-2a activates multiple biologic effects which are not fully understood.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Basal cell and squamous cell skin cancer
- Follicular lymphoma
- Melanoma
- Neuroendocrine tumors
- Renal cancer
- Transplant conditioning regimens